z-logo
open-access-imgOpen Access
Lytic Enzymes of Aspergillus piperis as a Tool for Attacking Some Phytopathogenic Fungi In vitro with Special Reference to its Cytotoxicity
Author(s) -
Samah Abd El-Kader El-Debaiky,
Anwer El-Badry
Publication year - 2021
Publication title -
journal of pure and applied microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.149
H-Index - 16
eISSN - 2581-690X
pISSN - 0973-7510
DOI - 10.22207/jpam.15.4.16
Subject(s) - sclerotinia sclerotiorum , lysis , sclerotinia , microbiology and biotechnology , cytotoxicity , lytic cycle , biology , fusarium oxysporum , enzyme , chitinase , hypha , extracellular , pathogen , biochemistry , in vitro , botany , immunology , virus
The antagonistic activity of Aspergillus piperis against Fusarium oxysporum f. sp. fabae (FOF) and Sclerotinia sclerotiorum were examined and showed multiple signs of hyphal interactions. Microscopic examination of contact regions among A. piperis and each pathogen revealed distinct enzymatic lysis of pathogenic hyphal cell walls. Therefore, it is important to estimate the lytic enzyme activity of A. piperis. Extracellular lytic enzymes are important offensive forces for A. piperis as a biological control agent. Chitinase, phospholipase, and protease recorded relatively high activity from a culture age of 10 days (82.3, 42.4, and 6.2 U/ml, respectively). Enzymatic persistence was measured at room temperature, recording relatively long periods, saving 54%, 46%, and 21% of their activity, respectively. The cytotoxicity of the crude culture filtrate of A. piperis was examined in MCF7 and WI38 human cell lines. The cell viability (IC50) value of the fungal filtrate was estimated after 24 h and 48 h. The results revealed that IC50 values against the MCF7 cell line were inoperative after 24 h and were recorded 80 μg/ml after 48 h. In contrast, IC50 values against the WI38 cell line were 85.69 and 69.8 μg/ml after 24 and 48 h, respectively.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here